mynth
← DATABASE
04/2024MajorityLBO

Kühne Holding takes majority stake in Aenova Group

GERMANY Life Sciences / Pharma & Biotech / CDMO EV €1–10bn

Context

Kühne Holding AG has entered into a definitive agreement to acquire a majority stake in Aenova Group from the international investment firm BC Partners. In a move to ensure continuity and strategic alignment, funds advised by BC Partners will reinvest alongside Kühne Holding to maintain a minority position in the company. The transaction was structured and executed in close partnership with E3X Partners, acting as the lead advisor and investment partner for the Kühne family vehicle. The strategic rationale for the acquisition is focused on expanding Kühne Holding’s portfolio into the pharmaceutical services sector, attracted by Aenova’s strong financial foundation and long-term growth prospects. Under BC Partners' ownership, Aenova achieved record financial results and established itself as a top-ten global CDMO. The new ownership structure is designed to transition the company from a traditional private equity cycle to a long-term "evergreen" investment horizon, providing the stability needed to build highly sought-after technology platforms and specialized development services.

In the past, Aenova Group was acquired by BC Partners in 2012 as part of its expansion strategy.

Aenova Group, which reported an EBITDA margin of [members only] in 2023, is valued in this transaction at an EV/EBITDA multiple of 10x–18x.

-> Deep-dive in Healthcare & Pharma market trends

Target

The Aenova Group is a leading global contract development and manufacturing organization (CDMO) serving the pharmaceutical and healthcare industries. Headquartered in Starnberg, Germany, the company operates as a comprehensive "one-stop shop" for the development, production, and packaging of a vast array of drug products. Its technical capabilities span all common dosage forms (including solid, semi-solid, liquid, sterile, and non-sterile applications) across both human and animal health. The group is particularly noted for its expertise in handling diverse active ingredient classes, ranging from standard pharmaceuticals to specialized food supplements, with high-containment capabilities (OEB 1 to 5). Its business model focuses on providing end-to-end supply chain services to global pharma companies, supported by a network of 14 specialized manufacturing sites across Europe and the USA. By combining operational excellence in conventional manufacturing with advanced technology platforms, Aenova addresses the complex regulatory and technical requirements of the modern pharmaceutical market, positioning itself as one of the ten largest CDMOs worldwide.

Ent. Value

€1–10bn

Equity Value

[members only]

Multiples

EV / Revenue

1x–3x

EV / EBITDA

10x–18x

EV / EBIT

[members only]

Historical Financials (EUR)

Year
Rev
EBITDA
EBIT
2023
€450–900M
€100–200M
[members only]
2022
€450–900M
€100–200M
[members only]

Other operations with Aenova Group

Other operations with Aenova Group
DateAcquirerTargetCountrySector
08/2012BC PARTNERSAENOVA GROUPGERMANYCDMO

Similar deals in Life Sciences

Similar deals in Life Sciences
DateAcquirerTargetCountrySector
05/2024GTCRSURMODICSUNITED STATESMedical Devices
05/2024BRUKERELITECH GROUPFRANCEDiagnostic Equipment
03/2024ADVANCED MEDICAL SOLUTIONS GROUPPÉTERS SURGICALFRANCEMedical Consumables
01/2024MERCK & CO.HARPOON THERAPEUTICSUNITED STATESR&D Biotech
12/2023MARLE GROUPNOWAKFRANCEImplants & Prosthetics
11/2023PARAGONPRIMEDGERMANYMedical Consumables
11/2023AMETEKPARAGON MEDICALUNITED STATESMedical Devices
11/2023ANJAC BEAUTY & HEALTHSTEPHIDFRANCECDMO
10/2023LUXEMPARTALPHACAPSGERMANYNutrition & Dietary Supplements
10/2023RESONETICSNITINOL BUSINESSUNITED STATESMedical Devices

REFERENCES

Valuation range: EV €1–10bn

Revenue range: €450–900M

EBITDA range: €100–200M

EV/Revenue range: 1x - 3x

EV/EBITDA range: 10x - 18x

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of Aenova Group by Kühne Holding are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

FAQ

What transaction does this page cover?

This page covers the acquisition of a majority stake in Aenova Group, a German company specialised in Pharma & Biotech, by Kühne Holding in 2024, structured as a leveraged buyout (LBO). This followed an earlier holding cycle initiated in August 2012, when the company was acquired by BC Partners.

How was the acquisition of Aenova Group by Kühne Holding valued, and what multiples were paid?

mynth displays the transaction’s enterprise value within the €1–10bn band, its EV/EBITDA multiple within the 10x - 18x range, and its EV/revenue multiple within the 1x - 3x range. Exact figures are available to members.

What were Aenova Group’s revenue and EBITDA at the time of the deal?

At the time of the transaction, Aenova Group generated annual revenue estimated in the €450–900M range and EBITDA in the €100–200M bracket (FY 2023). Detailed financial figures are available to members.

What sources support the information on this transaction?

Transaction data and operational intelligence were compiled from independent financial press reporting by specialized M&A publications.

What is mynth?

mynth is the first free M&A database dedicated to Small & Mid-Cap transactions. We centralize Enterprise Values, revenue multiples, EBITDA multiples and transaction financials that are typically locked behind five-figure subscriptions on platforms like Capital IQ or Mergermarket. On mynth, searching and browsing deals is completely free. Our mission is simple: make professional-grade valuation intelligence accessible to every M&A advisor, independent consultant, Private Equity professional and student, without the burden of expensive annual licenses.